Greenwich LifeSciences Alerts Nasdaq of Late Q1 2026 10-Q Filing, Trading Unaffected
GLSI•Greenwich LifeSciences received a Nasdaq notice on May 20, 2026 for noncompliance with Listing Rule 5250(c)(1) due to its late Form 10-Q for the quarter ended March 31, 2026. The notice does not affect the Nasdaq Capital Market listing, but continued delay could expose the company to delisting actions.
1. Nasdaq Notice of Late Form 10-Q Filing
On May 20, 2026, Greenwich LifeSciences received notification from the Nasdaq Listing Qualifications Department that it has not filed its Quarterly Report on Form 10-Q for the period ended March 31, 2026, resulting in noncompliance with Listing Rule 5250(c)(1). The notice confirms that trading of the company’s common stock on the Nasdaq Capital Market continues without interruption.
2. Potential Delisting Risks and Clinical Focus
Failure to cure the late filing by Nasdaq’s deadline could lead to formal delisting proceedings and trading suspension. Meanwhile, Greenwich remains focused on advancing its Phase III FLAMINGO-01 trial of GLSI-100 immunotherapy to prevent breast cancer recurrences.
